We Are Working to Improve Cardiovascular Health
Amarin’s Innovation in Cardiovascular Disease (CVD) Management
Working together to advance pathways in cardiovascular risk management
Cardiovascular disease management requires commitment and innovation. Despite optimal management of risk factors such as low-density lipoprotein cholesterol (LDL-C), many patients remain at risk of cardiovascular events.1 To reduce the burden of CVD, emerging therapeutic modalities should be explored to address drivers of residual risk.1
To provide effective cardiovascular prevention, it is crucial to share information on the evolving CVD landscape and discuss central questions in CVD management.
How can we fight cardiovascular disease today?
- Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7:88.
- Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.
We continue to share clinical trial results of all sponsored Phase I, Phase II, Phase III and Phase IV clinical trials of Amarin marketed products conducted anywhere in the world on www.clinicaltrials.gov. Amarin also seeks to publish study results through peer-reviewed journals and scientific conferences.
This website is intended for residents of the UK only. It is available to the general public for informational purposes only and should not be used for diagnosis or treatment of a health problem or disease. It is not intended as a substitute for consultation with a healthcare provider. Please consult your healthcare provider for further advice.